Assessing Host-Directed Activators for Liver-Stage Malaria

Status
Completed
Start date
End date
Start stage
Screening
End stage
Screening
Disease
Malaria
Research areas
Drug

Dr. Kaushansky was interested in accessing a class of compounds targeting a specific host protein, as she had previously shown that activating this protein might be an effective therapeutic strategy against liver-stage malaria. BVGH connected Dr. Kaushansky with Pfizer, who provided a novel activator compound to support her antimalarial drug discovery efforts.